Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Drugs Made In America Acquisition II (DMII)

Annual Return

Since Dec 3, 2025, DMII has had an average annual return of +2.13%, underperforming the benchmark SPY, which returned +10.33% annual.

20262025
+1.93%+0.20%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+0.71%+0.10%-0.10%+0.51%+0.39%+0%+0.30%+1.93%
2025+0.20%+0.20%

Drawdown analysis of Drugs Made In America Acquisition II (DMII)

The maximum drawdown for the DMII was -0.70%, occurring on Mar 6, 2026. Recovery took 38 trading sessions.

The current DMII drawdown is -0.10%.

DepthStartTo BottomBottomTo RecoverEndTotal
-0.70%Feb 3, 202622Mar 6, 202638Apr 30, 202660
-0.50%Jun 17, 20266Jun 26, 2026OngoingOngoingOngoing
-0.40%Dec 19, 20251Dec 22, 202514Jan 13, 202615
-0.20%Jan 22, 20262Jan 26, 20266Feb 3, 20268
-0.10%Dec 3, 20253Dec 8, 20259Dec 19, 202512
-0.10%Jan 16, 20261Jan 20, 20262Jan 22, 20263
-0.10%Apr 30, 20263May 5, 20264May 11, 20267
-0.10%May 26, 20263May 29, 20265Jun 5, 20268
-0.10%Jun 9, 20262Jun 11, 20264Jun 17, 20266